retatrutide 2025 trial results Lilly's shows 28% weight loss, but increased side effects First Retatrutide phase 3 data,

Various studies have attempted to quantify how much fat versus muscle mass is being lost when using GLP-1 agonists and the results vary anywhere from 20 to 50% of total weight loss as lean body mass (3) (muscle mass)

The search period extended from January 1990 through December 2025 to capture both foundational mechanistic research on testosterone signaling and contemporary clinical trials evaluating GLP-1 receptor agonists and testosterone replacement therapy

Without a foundation of mechanical eating and stabilised blood sugar through nutrition, this return can feel overwhelming

For someone working hard to maintain a calorie deficit, this sudden return of appetite can be frustrating and may lead to a plateau in weight loss progress

Knowing what to expect can ease the adjustment period and help you stay focused on your health goals

If you experience symptoms such as persistent severe abdominal pain, difficulty swallowing, or unexplained swelling around the neck area, its important to alert your provider as soon as possible